Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Spravato
Spravato
FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment
CNBC
Tue, 01/21/25 - 11:34 am
JNJ
FDA
major depressive disorder
Spravato
ketamine
Spravato is just the beginning in a new wave of depression meds
Pharma Voice
Mon, 11/11/24 - 11:26 am
JNJ
Spravato
depression
drug development
J&J’s comeback kid Spravato heads for blockbuster status
Pharma Voice
Fri, 10/25/24 - 11:13 am
JNJ
esketamine
Spravato
J&J seeks expanded approval for antidepressant Spravato
BioPharma Dive
Mon, 07/22/24 - 06:43 pm
JNJ
depression
Spravato
As J&J outlines bullish pipeline goals, neuroscience pipeline takes a starring role
Fierce Biotech
Wed, 12/6/23 - 09:15 pm
JNJ
Neuroscience
Spravato
major depressive disorder
J&J’s Spravato Bests Quetiapine in Phase III Head-to-Head Depression Study
BioSpace
Thu, 10/5/23 - 10:14 am
JNJ
clinical trials
Spravato
treatment-resistant depression
depression
Quetiapine
Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint
Clinical Trials Arena
Sat, 11/26/22 - 07:17 pm
Janssen
JNJ
clinical trials
Spravato
treatment-resistant depression
FDA expands use of controversial J&J antidepressant
Beckers Hospital Review
Wed, 08/5/20 - 12:01 am
FDA
JNJ
Spravato
treatment-resistant depression
major depressive disorder
ketamine
Trump touted a new antidepressant as a solution for veterans. Only 15 have been treated
Stat
Mon, 01/6/20 - 10:09 am
Donald Trump
veterans
esketamine
major depression
Spravato
JNJ
Janssen
AbbVie's blockbuster hopeful Rinvoq, J&J's Spravato eye EU rollouts, thanks to new backing
Fierce Pharma
Fri, 10/18/19 - 07:40 pm
AbbVie
Rinvoq
Europe
JNJ
Spravato
J&J seeks wider use of its Spravato antidepressant in US
Pharmaforum
Thu, 10/3/19 - 10:51 am
JNJ
FDA
Spravato
suicide
antidepressants
J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in?
Fierce Pharma
Tue, 09/10/19 - 11:31 am
JNJ
clinical depression
high-risk depression
Spravato
physicians
payers
Trump Wants the VA to Get as Much of This Drug as It Can
Motley Fool
Wed, 08/28/19 - 10:44 pm
veterans
JNJ
Spravato
Donald Trump
J&J depression drug Spravato gets half-hearted backing from VA doctors despite Trump's zeal
Fierce Pharma
Mon, 06/24/19 - 07:21 pm
JNJ
Spravato
Veteran's Affairs
Donald Trump
depression
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Fierce Pharma
Fri, 06/21/19 - 11:33 pm
Novartis
Mayzent
JNJ
Spravato
ICER
J&J gains an enthusiastic endorsement from President Donald Trump for their big new drug Spravato
Endpoints
Thu, 06/13/19 - 10:00 am
Donald Trump
JNJ
Spravato
depression
veterans
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
KHN
Tue, 06/11/19 - 11:41 pm
FDA
Janssen
Spravato
esketamine
major depressive disorder
Study Finds Ketamine Nasal Spray Effective For Treating Depression: What You Should Know
Forbes
Thu, 05/23/19 - 10:45 pm
depression
ketamine
esketamine
Spravato
JNJ
Janssen
ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’
Endpoints
Fri, 05/10/19 - 10:20 am
JNJ
drug pricing
antidepressants
esketamine
Spravato
ICER
J&J prices ketamine-like depression treatment at $590-$885 for two doses
Reuters
Fri, 03/8/19 - 09:35 am
JNJ
Spravato
depression
drug pricing
esketamine
Pages
1
2
next ›
last »